By Helena Smolak
Qiagen raised its earnings outlook for the year after higher first-quarter sales, sending shares higher despite a broader market decline.
In European morning trade, shares of Qiagen are up 1.8% at 35.95 euros, having risen as much as 2.4% earlier in the session. This is against the Stoxx Europe 600 Health Care index and broader Stoxx Europe 600 having fallen 4% and 4.8%, respectively. Qiagen's stock is down 16.5% in the year to date.
The Netherlands-based life science company said Sunday that it now expects adjusted earnings per share to be around $2.35 for 2025, from previous guidance of $2.28.
The company forecasts its adjusted operating income margin to be above 30% for the year, and expects to hit its midterm target of at least 31% much earlier than 2028, as previously anticipated.
The company said its outlook includes current business trends, such as headwinds from recently announced U.S. import tariffs but a better-than-expected tax environment.
Qiagen's net sales grew 5%, or 7% at constant exchange rates, to $483 million in the first quarter on higher demand for its gastrointestinal and meningitis testing.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 07, 2025 06:22 ET (10:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.